Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EBT (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed EBT for 15 consecutive years, with $4254.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 128.65% year-over-year to $4254.0, compared with a TTM value of -$398294.0 through Oct 2025, up 47.28%, and an annual FY2025 reading of -$94260.0, up 87.52% over the prior year.
  • EBT was $4254.0 for Q4 2025 at Pharma-Bio Serv, up from -$313877.0 in the prior quarter.
  • Across five years, EBT topped out at $2.3 million in Q3 2021 and bottomed at -$4.8 million in Q4 2021.
  • Average EBT over 5 years is -$14270.8, with a median of $120347.5 recorded in 2022.
  • Peak annual rise in EBT hit 194.14% in 2021, while the deepest fall reached 3248.42% in 2021.
  • Year by year, EBT stood at -$4.8 million in 2021, then surged by 104.82% to $231044.0 in 2022, then tumbled by 122.4% to -$51765.0 in 2023, then surged by 71.31% to -$14849.0 in 2024, then soared by 128.65% to $4254.0 in 2025.
  • Business Quant data shows EBT for PBSV at $4254.0 in Q4 2025, -$313877.0 in Q3 2025, and -$98322.0 in Q2 2025.